Health
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC)1Data for zongertinib monotherapy and in combination in other HER2-altered solid tumors, including breast, colorectal and esophageal cancers, shows encouraging early signals2-4Updated data adds to the growing evidence base of obrixtamig in extens
About this update from Bayer Ag
[{"type":"image","alt":"Boehringer Ingelheim Limited","displaySize":"","headline":null,"caption":"Boehringer Ingelheim Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/bef5cffde163baaa9d093287cb47484a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dodbKKwFI64qy97EAZYlMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNw--/https://media.zenfs.com/en/globenewswire.com/bef5cffde163baaa9d093287cb47484a","width":300,"height":91},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/dodbKKwFI64qy97EAZYlMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNw--/https://media.zenfs.com/en/globenewswire.com/bef5cffde163baaa9d093287cb47484a","width":300,"height":91}},"lazy":false},{"type":"text","content":"Not intended for US and UK media","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC)1","length":232,"tagName":"p"}]},{"val":[{"type":"text","content":"Data for zongertinib monotherapy and in combination in other HER2-altered solid tumors, including breast, colorectal and esophageal cancers, shows encouraging early signals2-4","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated data adds to the growing evidence base of obrixtamig in extensive‑stage small cell lung cancer (ES‑SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC)5,6","length":192,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":609,"olType":false},{"type":"text","content":"Ingelheim, Germany and Ridgefield, Conn., US – At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Boehringer Ingelheim will present new data from across its robust oncology clinical development program. Key data includes patient-reported outcomes with HERNEXEOS® (zongertinib tablets) as an initial orally administered treatment option for HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) and early results evaluating zongertinib in other types of cancer driven by HER2 alterations.1-4 Updated data for obrixtamig...